:::info CLINICAL MONOGRAPH AVAILABLE
For a highly detailed, clinical-grade review of mesenchymal stem cells, autologous vs. allogeneic sources, paracrine secretome mechanisms, dosage protocols, and extensive safety data, please see our dedicated clinical page:
Stem Cell Therapy (Clinical Monograph)
:::
Stem cell therapy involves the administration of stem cells to promote tissue regeneration and potentially reverse age-related damage. While promising in preclinical studies, clinical evidence for longevity applications remains limited and largely experimental [1][2].
Stem cells have the unique ability to differentiate into various cell types and potentially replace damaged or senescent cells. This regenerative capacity makes them attractive for longevity interventions [1:1]. However, the modern clinical paradigm has shifted from direct cellular differentiation to paracrine-mediated signaling—wherein stem cells act as regulatory factories that secrete growth factors and exosomes to rejuvenate existing host tissues [1:2][3].
Stem cells promote tissue rejuvenation through:
Current clinical evidence is characterized by:
For complete trial lists, p-values, and evidence grading, see the Evidence summary table in the Clinical Monograph.
Pittenger MF, Discher DE, Péault BM, et al. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019;4:22. https://www.nature.com/articles/s41536-019-0083-6 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25(5):829-848. https://journals.sagepub.com/doi/10.3727/096368915X689622 ↩︎ ↩︎ ↩︎ ↩︎
Rudnitsky E, Braiman A, Wolfson M. Mesenchymal stem cells and their derivatives as potential longevity-promoting tools. Biogerontology. 2025; PMID: 40259142. https://pubmed.ncbi.nlm.nih.gov/40259142/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Hum C, Poliwoda J, Lalu M, et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Transl Med. 2026; PMID: 42246109. https://pubmed.ncbi.nlm.nih.gov/42246109/ ↩︎ ↩︎ ↩︎
Ruiz JG, Oliva AA Jr, Ramdas KN, et al. Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty. Cell Stem Cell. 2026; PMID: 41747733. https://pubmed.ncbi.nlm.nih.gov/41747733/ ↩︎
Yousefi K, Ramdas KN, Ruiz JG, et al. The Design and Rationale of a Phase 2b, Randomized, Double-Blinded, and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Lomecel-B in Older Adults with Frailty. J Frailty Aging. 2022; PMID: 35441200. https://pubmed.ncbi.nlm.nih.gov/35441200/ ↩︎
Awad G, Saad JP, Hamyeh A, et al. Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. Clin Rheumatol. 2026; PMID: 41863718. https://pubmed.ncbi.nlm.nih.gov/41863718/ ↩︎
Hare JM, DiFede DL, Rieger AC, et al. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. J Am Coll Cardiol. 2017; PMID: 27856208. https://pubmed.ncbi.nlm.nih.gov/27856208/ ↩︎